Providing Resources for  Development Stage Life Science Companies One Carlson Parkway, Suite 124, Plymouth, MN 55447 www.t...
Table of Contents <ul><li>Overview </li></ul><ul><li>Development/Acceptance Process </li></ul><ul><li>Managing Directors <...
Overview
<ul><li>Established in 2009 to support the needs of development stage life science companies. </li></ul><ul><li>Management...
<ul><li>In today’s marketplace these companies must:  </li></ul><ul><ul><li>Have creditable technology from an appropriate...
Development/Acceptance Process
 
<ul><li>Technology Trust Process Timeline-Phase 1 </li></ul><ul><li>Technology Trust introduced to companies that are deve...
<ul><li>Technology Trust Process Timeline-Phase 2 </li></ul><ul><li>Upon acceptance of engagement letter we: </li></ul><ul...
<ul><li>Technology Trust Process Timeline-Phase 3 </li></ul><ul><li>We place calls into the key investor groups during the...
<ul><li>Technology Trust has the structure and the resources to do exceptional due diligence, market intelligence, and pro...
Managing Directors
Maurice (Maury) Taylor <ul><li>Founding Managing Director of Technology Trust. </li></ul><ul><li>Was CEO of CHdiagnostics,...
John Hustad <ul><li>Founding Managing Director of Technology Trust. </li></ul><ul><li>Was President of Windsor Consulting ...
References <ul><li>Earl Beitzel   Vice President, Finance and Business Development </li></ul><ul><li>Allina Hospitals and ...
Associate Partners
<ul><li>Paul J. Axt  – Product and Market Research Analyst </li></ul><ul><li>Ann Quinlan-Smith  – Clinical Strategy, Regul...
Upcoming SlideShare
Loading in …5
×

Technology Trust 08 24 09 Power Point Final

351 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
351
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Technology Trust 08 24 09 Power Point Final

  1. 1. Providing Resources for Development Stage Life Science Companies One Carlson Parkway, Suite 124, Plymouth, MN 55447 www.technologytrust.org
  2. 2. Table of Contents <ul><li>Overview </li></ul><ul><li>Development/Acceptance Process </li></ul><ul><li>Managing Directors </li></ul><ul><li>References </li></ul><ul><li>Associate Partners </li></ul><ul><li>Life Science Industry </li></ul><ul><li>Executive Summary </li></ul>
  3. 3. Overview
  4. 4. <ul><li>Established in 2009 to support the needs of development stage life science companies. </li></ul><ul><li>Management has extensive experience with the support and creation of these types of companies and understands their unique needs. </li></ul><ul><li>Management has written business plans for life science companies and was the leadership that developed: medical devices, pharmaceuticals, healthcare services and bio technology – from conception through numerous rounds of financing – becoming a public company and reaching over one billion dollars in annual revenue. </li></ul><ul><li>Large clinical institutions and academic centers have research communities that develop propriety life science technology. Once these technologies emerge as having viable potential, they are normally surrounded with significant intellectual property and are either sold off for a royalty payment or incubated – wherein they are provided the initial assets of a limited number of people and some financial support. They then work towards the goal of proving that the technology has some viability and is worthy of additional outside funding and the opportunity to advance the technology to commercialization. </li></ul>
  5. 5. <ul><li>In today’s marketplace these companies must: </li></ul><ul><ul><li>Have creditable technology from an appropriate source, </li></ul></ul><ul><ul><li>Have the technology be sufficiently advanced to assure that it is viable, </li></ul></ul><ul><ul><li>Have enough intellectual property to demonstrate that it is unique and defendable, </li></ul></ul><ul><ul><li>Have a reasonable regulatory pathway, </li></ul></ul><ul><ul><li>Have good assurance that it will be reimbursable by CMS and private insurance companies, less than five years to commercialization, </li></ul></ul><ul><ul><li>Be producible and saleable at price points that ensure a reasonable profit, </li></ul></ul><ul><ul><li>Have a funding requirement that will provide an exceptional potential return to the company’s investors, management and employees, and </li></ul></ul><ul><ul><li>Have a significant impact on and improvement to the existing technique or procedure for the benefit of the patient and without undue effort to the healthcare provider. </li></ul></ul><ul><li>We have a number of source relationships that introduce us to these types of technologies to which we impose a structured process that enables us to conform, through our own research, to the above success criteria. Our associate partners apply a number of disciplines that cover: product research, financial analysis and investor suitability, medical/pharma suitability, strategic marketing, SEC/public company legal, audit and accounting, human resources, regulatory and quality assurance.   </li></ul>
  6. 6. Development/Acceptance Process
  7. 8. <ul><li>Technology Trust Process Timeline-Phase 1 </li></ul><ul><li>Technology Trust introduced to companies that are development stage life science companies. </li></ul><ul><li>The managing director group reviews initial material (generally a latest PowerPoint presentation, business plan or PPM) and determines if a meeting should be held to facilitate introductions. </li></ul><ul><li>The first meeting is attended by a Managing Director and Research Analyst. </li></ul><ul><li>Based on that discussion we may decide to proceed to an initial due diligence meeting which includes a review of: </li></ul><ul><li>1. The product </li></ul><ul><li>2. Its market position </li></ul><ul><li>3. Competition </li></ul><ul><li>4. Current company status </li></ul><ul><li>5. Financial condition and needs </li></ul><ul><li>6. Regulatory pathway </li></ul><ul><li>7. Reimbursement plan </li></ul><ul><li>8. Other critical factors </li></ul><ul><li>Upon acceptance we provide an engagement letter for CEO and/or BOD approval. </li></ul><ul><ul><li>Our goal is to accomplish this within four weeks from initial discussion. </li></ul></ul>
  8. 9. <ul><li>Technology Trust Process Timeline-Phase 2 </li></ul><ul><li>Upon acceptance of engagement letter we: </li></ul><ul><ul><li>Move to a more complete due diligence process </li></ul></ul><ul><ul><li>Work with the Company to produce a current PowerPoint presentation and Executive Summary. </li></ul></ul><ul><ul><li>We have $100,000.00 invested into the Company (equity fund) to pay for the cost of this three to five month process, which may include making the Company a “reporting company.” This process, therefore, does not disrupt the current working capital of the Company. Any unused funds are returned to the Company for addition to their working capital. </li></ul></ul><ul><ul><li>We prepare the Company to present itself to the 20 or more lead VC and Angel group organizations that we have established relationships. </li></ul></ul><ul><ul><li>Our goal is to accomplish this within six weeks. </li></ul></ul>
  9. 10. <ul><li>Technology Trust Process Timeline-Phase 3 </li></ul><ul><li>We place calls into the key investor groups during the prior phase and follow-up at this point as we prepare to set up introductions to the Company starting with: </li></ul><ul><ul><li>Our written executive summary </li></ul></ul><ul><ul><li>PowerPoint presentation </li></ul></ul><ul><ul><li>Telephone discussion </li></ul></ul><ul><ul><li>Physical visit </li></ul></ul><ul><ul><li>Make available to those interested investors our comprehensive due diligence books </li></ul></ul><ul><ul><li>We start with local investors and move to those wherever they are located </li></ul></ul><ul><ul><li>All costs are paid by the equity fund </li></ul></ul><ul><li>This phase we try to accomplish in four to six weeks. </li></ul>
  10. 11. <ul><li>Technology Trust has the structure and the resources to do exceptional due diligence, market intelligence, and provide on-going support services. We believe in the Imricor technology/products and the people who we trust will diligently work to make Imricor a commercial success. Technology Trust has sufficient relationships to secure for Imricor the necessary financing to make this commercialization possible and we will use our resources to ensure this happens on a timely basis. </li></ul><ul><li>We have the relationships to get Imricor’s principals in front of those investors who are interested in their technology, have the funds, and are currently making these types of investments. With management’s ability to present and support the Imricor story we expect to be successful. </li></ul>
  11. 12. Managing Directors
  12. 13. Maurice (Maury) Taylor <ul><li>Founding Managing Director of Technology Trust. </li></ul><ul><li>Was CEO of CHdiagnostics, a worldwide developer, manufacturer and distributor of diabetes-related medical devises. </li></ul><ul><li>Was Founder and Chairman of ProUroCare Inc. which develops, manufactures and distributes image-guided diagnostic systems in the treatment of prostate disease. </li></ul><ul><li>Was Chairman of Whittier Scripps Institute of LaJolla, California and provided numerous functions that included strategic planning for the International Diabetes Center of Minnesota. </li></ul><ul><li>Named 1994 Entrepreneur of the Year in Healthcare by Inc. Magazine. </li></ul><ul><li>Has been instrumental in the creation and growth of numerous companies which have been successfully sold – some examples of which are Chronimed/Medgenesis, Orphan Medical, Inc., Chronimed Publishing, Home Service Medical and Linguistics Technology. </li></ul><ul><li>Served in leadership positions in such firms as Summit Gear, Inc. and Associated Qualcom Inc., and served as International Director for T.N.M. Trading Company, A.G., of Zurich, Switzerland. </li></ul><ul><li>Office 952-476-9055 </li></ul><ul><li>Cell 952-292-1336 </li></ul><ul><li>[email_address] </li></ul>
  13. 14. John Hustad <ul><li>Founding Managing Director of Technology Trust. </li></ul><ul><li>Was President of Windsor Consulting Group. </li></ul><ul><ul><li>Windsor Group provides consulting services to companies on financing/funding, risk management and real estate. </li></ul></ul><ul><ul><li>Windsor Group also offers business plan development, captive insurance management and finite reinsurance exposure analysis. </li></ul></ul><ul><li>Has more than 18 years experience in solving unique business needs for Fortune 1000 and private companies throughout the United States. </li></ul><ul><li>Was Director of Sales at Aon Corporation. Areas of expertise include property, casualty, directors and officers’ liability, errors and omissions, malpractice and employment practices issues. </li></ul><ul><li>Assists clients with all aspects of corporate program design and implementation, providing funding opportunities, insurance and risk consulting, marketing and placement. </li></ul><ul><li>Received his B.A. in Marketing Management at the College of St. Thomas. </li></ul><ul><li>Has actively participated in a number of community organizations including The University of St. Thomas Alumni Association, Excelsior and Minneapolis Rotary Clubs, Twin West Chamber of Commerce and the Boys and Girls Clubs of Minneapolis. </li></ul><ul><li>Office 952-476-9055 </li></ul><ul><li>Cell 952-240-2160 </li></ul><ul><li>[email_address] </li></ul>
  14. 15. References <ul><li>Earl Beitzel Vice President, Finance and Business Development </li></ul><ul><li>Allina Hospitals and Clinics, 4050 Coon Rapids Blvd. NW, </li></ul><ul><li>Coon Rapids, MN 55433-2522 </li></ul><ul><li>763-236-8569 </li></ul><ul><li>Tom Hays III Principal of Nachman, Hays, and Brownstein </li></ul><ul><li>822 Montgomery Avenue, Narberth, PA 19072 </li></ul><ul><li>610-660-0060 </li></ul><ul><li>Marty McKinley CEO of Wells Fargo Asset Management </li></ul><ul><li>109 South 7th Street, Minneapolis, MN 55402 </li></ul><ul><li>612-673-8576 </li></ul><ul><li>Bjorn Honda Executive Vice President of RJF Agencies </li></ul><ul><li>6000 Nathan Lane N, Plymouth, MN 55442 </li></ul><ul><li>763-746-8507 </li></ul>
  15. 16. Associate Partners
  16. 17. <ul><li>Paul J. Axt – Product and Market Research Analyst </li></ul><ul><li>Ann Quinlan-Smith – Clinical Strategy, Regulatory, Quality Assurance </li></ul><ul><li>Dr. Bert Spilker – Design, Manufacturing, Marketing Pharmaceuticals </li></ul><ul><li>David Graff – Strategic Marketing and Sales Management </li></ul><ul><li>Paul Chestovich - SEC and Corporate Legal </li></ul><ul><li>Rachel D. Polson - Auditing and Accounting Services </li></ul><ul><li>Curtis P. Savstrom – Diverse Operations, Financial Management </li></ul><ul><li>Two Open Positions – Human Resources and Investor Relations </li></ul>

×